EnteroMedics Inc (ETRM) : Mpm Asset Management reduced its stake in EnteroMedics Inc by 0.01% during the most recent quarter end. The investment management company now holds a total of 74,206 shares of EnteroMedics Inc which is valued at $46,750 after selling 9 shares in EnteroMedics Inc , the firm said in a disclosure report filed with the SEC on May 11, 2016.EnteroMedics Inc makes up approximately 0.02% of Mpm Asset Management’s portfolio.
Other Hedge Funds, Including , Highlander Capital Management reduced its stake in ETRM by selling 5,559 shares or 76.94% in the most recent quarter. The Hedge Fund company now holds 1,666 shares of ETRM which is valued at $1,050. Hudson Bay Capital Management Lp added ETRM to its portfolio by purchasing 204,836 company shares during the most recent quarter which is valued at $129,047. EnteroMedics Inc makes up approx 0.02% of Hudson Bay Capital Management Lp’s portfolio.Manufacturers Life Insurance Company The reduced its stake in ETRM by selling 1 shares or 0.59% in the most recent quarter. The Hedge Fund company now holds 169 shares of ETRM which is valued at $106.Blackrock Institutional Trust Company N.a. reduced its stake in ETRM by selling 2 shares or 0.02% in the most recent quarter. The Hedge Fund company now holds 8,219 shares of ETRM which is valued at $5,178. Cambridge Investment Research Advisors sold out all of its stake in ETRM during the most recent quarter. The investment firm sold 1,055 shares of ETRM which is valued $791.
EnteroMedics Inc opened for trading at $0.612 and hit $0.7787 on the upside on Monday, eventually ending the session at $0.64, with a gain of 1.59% or 0.01 points. The heightened volatility saw the trading volume jump to 1,72,712 shares. Company has a market cap of $5.9 M.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology which is referred to as VBLOC therapy is designed to intermittently block the vagus nerve using high frequency low energy electrical impulses. The Company’s initial product is the Maestro System which uses VBLOC therapy to affect metabolic regulatory control limits the expansion of the stomach help control hunger sensations between meals reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product the Maestro Rechargeable System in the United States Australia the European Economic Area and other countries.